medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2022, Number 3

<< Back

Medicina & Laboratorio 2022; 26 (3)

Carcinoid crisis as a rare cause of distributive shock

Benítez-Patiño Y, Tibavizco-Palacios D

Language: Spanish
References: 17
Page: 297-305
PDF size: 92.76 Kb.


ABSTRACT

Neuroendocrine tumors are neoplasms that usually have a malignant clinical behavior. They arise from enterochromaffin-like and/or gastrin-producing cells. According to their anatomical location they can be classified as foregut tumors (af- fecting stomach, duodenum, lungs and pancreas), midgut tumors (affecting distal portion of the duodenum) and hindgut tumors (affecting transverse colon to rectum). Carcinoid syndrome, occurring in half of the cases at the time of diagnosis, is characterized by episodes of diarrhea, tachycardia, hypotension, flushing (due to telangiectasia), and heart valve disease depending on their severity. On the other hand, the carcinoid crisis, a rare complication that is related to episodes of shock, occur as a consequence of the release of vasoactive amines into the systemic circulation after a triggering event. Here we describe a case of a male patient with a history of neuroendocrine neoplasm, who after embolization of hepatic metastatic lesions presented a carcinoid crisis, ending with a vasodilatory shock, refractory to conventional treatment including octreotide and vasopressors, which resulted in the death of the patient. A discussion of the clinical report and a review of the available literature are presented, including the epidemiology, pathogenesis, diagnosis, clinical manifestations and treatment of this entity.


REFERENCES

  1. Bardasi C, Benatti S, Luppi G, Garajovà I, PiacentiniF, Dominici M, et al. Carcinoid crisis:A misunderstood and unrecognized oncologicalemergency. Cancers (Basel) 2022;14:662.https://doi.org/10.3390/cancers14030662.

  2. Pobłocki J, Jasińska A, Syrenicz A, Andrysiak-Mamos E, Szczuko M. The neuroendocrineneoplasms of the digestive tract: Diagnosis,treatment and nutrition. Nutrients 2020;12:1437.https://doi.org/10.3390/nu12051437.

  3. Jin C, Sharma AN, Thevakumar B, MajidM, Al Chalaby S, Takahashi N, et al. Carcinoidheart disease: Pathophysiology, pathology,clinical manifestations, and management.Cardiology 2021;146:65-73. https://doi.org/10.1159/000507847.

  4. Niederle MB, Hackl M, Kaserer K, NiederleB. Gastroenteropancreatic neuroendocrine tumours:the current incidence and staging basedon the WHO and European NeuroendocrineTumour Society classification: an analysis basedon prospectively collected parameters. EndocrRelat Cancer 2010;17:909-918. https://doi.org/10.1677/erc-10-0152.

  5. Sansone A, Lauretta R, Vottari S, Chiefari A,Barnabei A, Romanelli F, et al. Specific andnon-specific biomarkers in neuroendocrinegastroenteropancreatic tumors. Cancers (Basel)2019;11:1113. https://doi.org/10.3390/cancers11081113.

  6. Vargas-Martínez CC, Castaño-Llano R. Tumoresneuroendocrinos gastroenteropancreáticos.Rev Col Gastroenterol 2010;25:165-176.

  7. Wang R, Zheng-Pywell R, Chen HA, Bibb JA,Chen H, Rose JB. Management of gastrointestinalneuroendocrine tumors. Clin Med Insights EndocrinolDiabetes 2019;12:1179551419884058.https://doi.org/10.1177/1179551419884058.

  8. Fierro-Maya LF, Prieto C, Garavito-GG, González-C AM, Muleth Y, Carreño JA. Resultadosdel tratamiento multidisciplinario de tumoresneuroendocrinos de intestino delgado. Rev ColGastroenterol 2018;22:105-111.

  9. Mota JM, Sousa LG, Riechelmann RP. Complicationsfrom carcinoid syndrome: review ofthe current evidence. Ecancermedicalscience2016;10:662. https://doi.org/10.3332/ecancer.2016.662.

  10. Limbach KE, Condron ME, Bingham AE, PommierSJ, Pommier RF. Β-Adrenergic agonistadministration is not associated with secondarycarcinoid crisis in patients with carcinoid tumor.Am J Surg 2019;217:932-936. https://doi.org/10.1016/j.amjsurg.2018.12.070.

  11. Condron ME, Jameson NE, Limbach KE,Bingham AE, Sera VA, Anderson RB, et al.A prospective study of the pathophysiologyof carcinoid crisis. Surgery 2019;165:158-165.https://doi.org/10.1016/j.surg.2018.04.093.

  12. Condron ME, Pommier SJ, Pommier RF.Continuous infusion of octreotide combinedwith perioperative octreotide bolus does notprevent intraoperative carcinoid crisis. Surgery2016;159:358-365. https://doi.org/10.1016/j.surg.2015.05.036.

  13. Kinney MAO, Warner ME, Nagorney DM,Rubin J, Schroeder DR, Maxson PM, et al.Perianaesthetic risks and outcomes of abdominalsurgery for metastatic carcinoid tumours.Br J Anaesth 2001;87:447-452. https://doi.org/10.1093/bja/87.3.447.

  14. Clement D, Ramage J, SrirajaskanthanR. Update on pathophysiology, treatment,and complications of carcinoid syndrome.J Oncol 2020;2020:8341426. https://doi.org/10.1155/2020/8341426.

  15. Keskin O, Yalcin S. Carcinoid crisis in the intensivecare unit. In: Nates JL, Price KJ, eds. OncologicCritical Care. Cham: Springer InternationalPublishing; 2019. p. 1-7.

  16. Seymour N, Sawh SC. Mega-dose intravenousoctreotide for the treatment of carcinoidcrisis: a systematic review. Can J Anaesth2013;60:492-499. https://doi.org/10.1007/s12630-012-9879-1.

  17. van Diepen S, Sobey A, Lewanczuk R, SinghG, Sidhu S, Zibdawi M, et al. A case of acuterespiratory distress syndrome responsive tomethylene blue during a carcinoid crisis. CanJ Anaesth 2013;60:1085-1088. https://doi.org/10.1007/s12630-013-0026-4.




2020     |     www.medigraphic.com